Category

Article of the week
This article was originally posted by Journal of Experimental Pharmacology Offidani et al. Journal of Experimental Pharmacology 2021:13 245–264 Offidani, Corvatta, Morè & Olivieri Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. On behalf of Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) please find below our article of the week. 3-year follow up of the phase III CASTOR study with independent expert commentary provided by MSAG chair Professor H. Miles Prince AM (Research...
Continue Reading
I have recently completed the Alps 2 Ocean (A2O) 315km ride over 6 days which is one of my greatest physical accomplishments in recent times and have been asked to write something about my journey. I will start with myself. Diagnosed with Kappa Light Chain myeloma 8.5 years ago after the T9 on my spinal...
Continue Reading
Background | Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infusion-related reactions are common. Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. Methods...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). This study evaluated addition of daratumumab (D) to RVd in ASCTeligible NDMM patients. Patients (N=207) were randomized...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most common hematologic malignancy worldwide, characterized by excessive proliferation of monoclonal plasma cells. The development of novel anti-MM agents has expanded treatment options for MM patients and improved out-comes. Despite recent treatment advances, MM remains incurable, with...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. The article from Australia’s National Centre for Infections in Cancer (NCIC, Peter MacCallum Cancer Centre) includes MSAG members Prof Jeff Szer and A/Prof Peter Mollee as co-authors.  Along with this guide for health care professionals please find attached the guide for patients, produced by...
Continue Reading
There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple Myeloma (MM) patients, as defined equally either by Multicolor Flow Cytometry (MFC) or by Next Generation Sequencing (NGS) technologies. At present, modern technologies allow to detect up to one on 104 or...
Continue Reading
Renal impairment (RI) is a poor prognostic factor in patients with multiple myeloma (MM). Despite improvements in survival with the introduction of novel therapies in recent years, RI remains one of the most common complications with an incidence of 20% to 50% at diagnosis, and approximately 5% to 10% of MM patients are dialysis-dependent.1-3 The...
Continue Reading
Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but prospective data on elderly non-transplant eligible patients is limited. A total of 155 patients aged 70 years or older with newly diagnosed multiple myeloma who received at least one cycle of CyBorD chemotherapy in three...
Continue Reading
1 2

Floor 7, 90 The Terrace
Wellington Central
New Zealand